• Exelixis entered a clinical development collaboration with Merck for the planned Phase 3 STELLAR-316 pivotal trial in resected stage II/III colorectal cancer.
• Merck will supply KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous use in combination with zanzalintinib.
• Exelixis will sponsor STELLAR-316, which will test zanzalintinib with or without KEYTRUDA QLEX in patients who are molecular residual disease-positive with no radiographic evidence of disease.
• The primary endpoint is disease-free survival, with circulating tumor DNA clearance as a key secondary endpoint.
• Exelixis expects to start the trial in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605190800BIZWIRE_USPR_____20260519_BW571771) on May 19, 2026, and is solely responsible for the information contained therein.